Inclusion Criteria:

- Healthy adult males

- Participants aged ≥18 years and ≤55 years old

- Body weight: Body mass index (BMI) between 19.0 and 26.0 kg/m2 (including borderline
values), body weight no less than 50.0 kg.

- Voluntarily participate in the clinical trial and sign the informed consent

- Able to communicate well with the investigator and able to complete the trial in
accordance with the protocol

Exclusion Criteria:

- Participants who have abnormalities and clinical significance after comprehensive
physical examination, vital signs, routine laboratory tests, thyroid function, chest
CT, abdominal ultrasound, etc.

- Participants whose 12-lead electrocardiogram test results show corrected QT interval
≥450 msec

- Participants who is positive for Hepatitis B Surface Antigen, Hepatitis C Antibody,
HIV Antibody and Syphilis Antibody

- Participants who have used any drug that inhibits or induces hepatic drug
metabolizing enzymes within 30 days prior to the screening period

- Participants who have used any prescription medication, over-the-counter medication,
herbal or dietary supplements, such as vitamins, calcium supplements, within 14 days
prior to the screening period

- Participants who have a history of any clinically serious disease or
disease/condition that, in the opinion of the investigator, may affect the results
of the test, including, but not limited to, a history of circulatory, respiratory,
endocrine, neurological, gastrointestinal, urological, or hematological,
immunological, psychiatric, and metabolic disorders

- Participants who have any condition that may affect drug absorption, e.g.,
gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy, history of
inflammatory bowel disease

- Participants who have history of organic heart disease, heart failure, myocardial
infarction, angina pectoris, unexplained arrhythmia, ventricular tachycardia,
atrioventricular block, QT prolongation syndrome, or symptoms of QT prolongation
syndrome, and a family history of the disease (as evidenced by genetic
predisposition or by the death of a close family member from a cardiac cause at a
young age).

- Participants who have undergone major surgery within 6 months prior to the screening
period or whose surgical incisions have not completely healed; major surgery
includes, but is not limited to, any surgery with significant risk of hemorrhage,
prolonged general anesthesia, or incisional biopsy or significant traumatic injury

- Participants who have specific allergic history, such as those with a known history
of allergy to two or more substances; or those who, in the judgment of the
investigator, may be allergic to the test drug or its excipients

- Participants who have perianal disease with regular/ongoing blood in stool,
irritable bowel syndrome, inflammatory bowel disease

- Participants who have habitual constipation or diarrhea

- Participants who are alcohol abusers or regularly drink alcohol in the 6 months
prior to the screening period, i.e., more than 14 units of alcohol per week (1 unit
= 360 mL of beer or 45 mL of spirits at 40% alcohol by volume or 150 mL of wine); or
an alcohol breath test result of >0 mg/dL at the time of the screening period

- Participants who smoked >5 cigarettes per day in the 3 months prior to the screening
period or habitually used nicotine-containing products and were unable to quit
during the trial period

- Participants who are substance abusers or use soft drugs (e.g., marijuana) in the 3
months prior to the screening period or use of hard drugs (e.g., cocaine,
amphetamines, phenylcyclohexylpiperidine, etc.) in the 1 year prior to the screening
period; or a positive urine drug test at the screening period

- Participants who consume grapefruit juice or excessive amounts of tea, coffee and/or
caffeinated beverages that cannot be stopped during the trial period

- Participants who are exposed to radiation for prolonged periods of time; or who have
had significant radiation exposure (≥2 chest/abdominal CTs, or ≥3 other types of
X-rays) or participated in radiopharmaceutical labeling tests within 1 year prior to
testing

- Participants who are with a history of needle and blood sickness, those who have
difficulty in blood collection or cannot tolerate venipuncture blood collection

- Participation in any other clinical trial (including clinical trials such as drugs
and devices) within 3 months prior to the screening period

- Participants who have vaccinated within 1 month prior to screening or scheduled to
be vaccinated during the trial period

- Participants who plan to have children or donate sperm during the trial and within 1
year after completion of the trial, or who do not agree that the subject and his/her
spouse should use strict contraception during the trial and within 1 year after
completion of the trial

- Participants who have had blood loss or donated up to 400 mL of blood within 3
months prior to the screening period, or those who have received a blood transfusion
within 1 month

- Participants who, in the opinion of the investigator, have any factors that make
participation in this trial inappropriate